By utilizing a less invasive implantation procedure and a less invasive non-blood contacting device, CorInnova's device is designed to eliminate up to 40% of the adverse events associated with LVADs - stroke, thrombus, gastrointestinal bleeding, kidney dysfunction, and right heart failure. CorInnova’s  device is designed to expand patient eligibility up to 50% , potentially providing longer life and higher quality of life due to anticipated shorter hospital stays and reduced adverse events. .  Moreover, the device should lead to cardiac restoration in much greater frequency than LVADs (1 to 2 1/2%) by correcting motion, reducing wall stress, and normalizing cytokine signaling – key factors in restorative cardiac remodeling.